

Evaluation of the oral component of Sjögren’s syndrome: An overview

Georges Aoun¹, Ibrahim Nasseh², Antoine Berberi³

Departments of ¹Oral Pathology and Diagnosis, ²Oral and Maxillofacial Radiology and ³Oral and Maxillofacial Surgery, Faculty of Dentistry, Lebanese University, Beirut, Lebanon

Corresponding author (email: <aoungorges@yahoo.com>)

Dr. Georges Aoun, Department of Oral Pathology and Diagnosis, Faculty of Dentistry, Lebanese University, Beirut, Lebanon.

Received: 02-06-16

Accepted: 05-07-16

Published: 25-07-16

Abstract

Sjögren’s syndrome is a chronic autoimmune disorder characterized by lymphocytic infiltration, and consequently hypofunction of lacrimal and salivary glands. The loss of salivary function induces oral dryness (xerostomia). This review focuses on methods for determining salivary gland function including clinical signs, salivary flow rate measurements (sialometry), analysis of salivary composition (sialochemistry), histopathological and radiologic examinations, and other recent advanced techniques.

Key words: *Biopsy, labial salivary gland, sialochemistry, sialography, sialometry, Sjögren’s syndrome, xerostomia*

INTRODUCTION

Sjögren’s syndrome (SS) is a chronic autoimmune disease, which was first described in 1933 by the Swedish ophthalmologist Henrik Sjögren. It is characterized by lymphocytic infiltration causing progressive destruction of exocrine glands, specifically the salivary and lacrimal glands, leading eventually to xerostomia and keratoconjunctivitis sicca.^[1,2]

SS is the second most common chronic systemic autoimmune disease affecting between 0.05 and 0.4% of the world population.^[3-5]

Although being relatively common, it is still difficult to be diagnosed because of the variability of its clinical presentations that range from mild cases of dryness, fatigue, and pain to severe systemic conditions involving multiple organs.^[6]

SS can occur alone (primary SS) or associated with other underlying autoimmune diseases (secondary SS) such as rheumatoid arthritis, scleroderma, and polymyositis.^[6-8]

Xerostomia is not pathognomonic to SS; it can be a symptom of other diseases (sarcoidosis, poorly controlled diabetes, systemic lupus erythematosus, etc.), an adverse effect of certain medications (antidepressants, antihistamines, diuretics, etc.) or previous treatment (radiation of the head and neck).

Thus, the evaluation of xerostomia in SS is as varied as variable. Indeed, the diagnosis based on clinical examination needs to be made by more specific tests studying the function of salivary glands. The main objective of this article was to review the different methods of exploration of the salivary glands and to clarify their diagnostic value.

Access this article online	
Quick Response Code:	Website: www.jispcd.org
	DOI: 10.4103/2231-0762.186802

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Aoun G, Nasseh I, Berberi A. Evaluation of the oral component of Sjögren's syndrome: An overview. J Int Soc Prevent Communit Dent 2016;6:278-84.

METHODS

Clinical signs

Xerostomia, frequently encountered in dental practice, is associated with:

- Increased risk of developing dental caries: The deficiency of the anticariogenic actions of saliva induce more aggressive tooth decay progress than normal. Caries may affect all teeth surfaces including the ones that are usually spared such as the cervical margins of the anterior mandibular and maxillary teeth^[9]
- Dental erosion: The normal saliva prevents demineralization of teeth^[10]
- Fungal infections especially oral candidiasis: The lack of antimicrobial agents contained in saliva leads to an opportunistic infection with *Candida* species^[11]
- Suppurative sialadenitis: Hyposalivation may result in bacterial entrance into the duct of the gland and consequently infection and swelling. The parotid is the mostly concerned^[12]
- Oral discomfort while chewing, swallowing, tasting, or speaking^[13]
- Problems for denture wearers such as denture instability, generalized mucosal soreness, and ulceration of the areas covered by the denture^[14]
- Oral mucosa alterations, among others, angular cheilitis, burning or tingling sensation^[15]
- Fissured, sticky, depapillated, and erythematous tongue^[15]
- Dysgeusia and intraoral halitosis possibly due to increased activity of halitogenic biofilm.^[15]

Measurement of salivary flow

Major and minor salivary glands generate saliva in different ways and flow rates. While the parotid gland produces saliva under stimulation (eating, sucking, chewing, or smelling a tasty meal), the submandibular secretes saliva continuously (without stimulation) keeping the mouth moist.

Salivary flow measurement (sialometry) is widely applied in diagnosing xerostomia. Several methods for collecting saliva have been reported, yet none is perfect. These methods are divided into two types: (1) Collection of the saliva present in the mouth known as the whole saliva technique (combined secretions of all salivary glands) and (2) collection directly from a specific salivary gland.^[16]

The collection of the whole saliva is commonly used. It is easy to perform, is quickly accomplished, and does

not require any collection device.^[17] However, in this technique, the collected saliva may be subject to the interference of nonsalivary elements such as epithelial cells and food debris.^[18]

Normally, unstimulated whole saliva flow rate is 0.3–0.4 ml/min; below 0.1 ml/min rate is considered abnormal.^[12] For the stimulated one, a rate less than 0.5 ml/gland in 5 min or less than 1 ml/gland in 10 min is significantly low.^[15]

For many researchers, the diagnostic value in SS is defined only by a reduced rate of secretion of unstimulated whole saliva.^[19-22] For others, many alterations in flow rate, not seen or less obvious when using the whole saliva, have been reported in patients with SS tested with the separate glandular saliva technique.^[23-25]

Pijpe *et al.* concluded in their study that early SS is accompanied by a reduction of all salivary glands function which becomes severe over time.^[26]

For Vissink *et al.*, among the salivary glands, in patients with SS, the parotid is the last one that is affected. This unclear mechanism is, in the same manner, observed in healthy elderly people in whom the capacity of saliva secretion by the parotid is not perturbed by age, whereas submandibular and sublingual glands physiologically present a decrease in their secretory capacity.^[27]

Finally, it is important to note that xerostomia may also result from a change in the composition of saliva from serous to mucous.^[28]

Chemical study of saliva

Chemical saliva study (sialochemistry) may show several characteristic changes in electrolytes and enzymes in SS due to the effect of an autoimmune attack on the secretory cells of the salivary glands.^[29] A study conducted by van der Reijden *et al.* concluded that the absolute concentrations of albumin, cystatin C, cystatin S, total IgA, and total protein (except amylase), were increased significantly in SS.^[29] In the same manner, a marked elevation in sodium and chloride in saliva is noted while phosphate concentration is reduced.^[17]

Baldini *et al.* conducted a study using a proteomic approach to analyze the saliva of patients with primary SS. They concluded that the salivary profile of these patients is characterized by a decrease in many secretory proteins (α -amylases precursor, carbonic anhydrase VI,

etc.), an increase in proteins related to the autoimmune response (β -2 microglobulin, IGKC protein, and rheumatoid factor D5 light chain), as well as an increase in the inflammatory proteins (alpha-enolase, lipocalin, and S100-A7 and A9 proteins).^[30]

In regards to the saliva pH, dos Anjos Corvo *et al.*, in their study, compared the salivary pH of individuals with SS to healthy individuals and found no statistically significant difference both in stimulated and nonstimulated total saliva.^[31]

Histopathological examination

The inflammatory cells infiltration in SS occurs in both major and minor salivary glands. The infiltrate contains, among others, T cells, B cells, macrophages, and natural killer cells. T and B cells predominate and the proportion of B cells increases with lesion severity.^[32] To perform the histopathological examination, a salivary gland biopsy is needed. For most researchers, minor salivary gland biopsy remains a highly used diagnostic procedure for oral salivary component of SS.^[33,34]

However, biopsy of a major salivary gland mainly the parotid is sometimes indicated when mucosa-associated lymphoid tissue (MALT) lymphoma, which can occur in SS, is suspected. MALT lymphomas mostly originate in the parotid gland.^[35]

Sampling is usually performed at the lower lip where 5–7 accessory glands are excised [Figure 1].

Histopathological examination may help to diagnose SS if it reveals a mononuclear infiltration with mostly periductal and/or perivascular distribution [Figure 2a and b].

The inflammatory infiltrate is quantified and an aggregation of ≥ 50 lymphocytes, plasma cells, or



Figure 1: Minor salivary glands biopsy through an incision in the lower lip

histiocytes is considered a focus.^[34,36] The number of focus in a surface of 4 mm² denotes the focus score.^[34,36]

The classical method for scoring SS biopsies is based on the Chisholm and Mason classification composed of 5 criteria [Table 1].^[36,37]

The focus score has been considered to be an index of severity of the salivary gland lesion in SS, with higher focus score related to acinar damage.^[33]

According to the Revised International Classification Criteria (RICC) and the Japanese Expert Criteria (JEC), a focus score of ≥ 1 is considered positive for SS diagnosis.^[34]

In their studies, Daniels *et al.* and Haldorsen *et al.* found that a focus score of ≥ 1 matches with the presence of keratoconjunctivitis sicca and low unstimulated but not stimulated salivary flow rates.^[38,39] In 1974, Tarpley *et al.* developed another classification of 5 grades also based on the focus scores [Table 2].^[40]

Table 1: Grading method as developed by Chisholm and Mason (1968)

Grade	Lymphocytes and plasma cells per 4 mm ²
Grade 0	No infiltrate
Grade 1	Slight infiltrate
Grade 2	Moderate infiltrate or less of 1 focus
Grade 3	1 focus
Grade 4	More than 1 focus

Table 2: Grading method as developed by Tarpley *et al.* (1974)

Grade	Infiltrate
Grade 0	No infiltrate, normal appearance
Grade 1	1 or 2 focus
Grade 2	Over 2 focus
Grade 3	Diffuse mononuclear infiltrate with partial acinar destruction
Grade 4	Diffuse infiltration with total acinar destruction




Figure 2: (a and b): Hematoxylin and eosin colored sections of minor salivary gland biopsy specimens showing lymphocytes infiltration

Although focus score may give some idea of the extent of the glandular infiltration, dealing with it to elaborate a final diagnostic in SS must be done carefully. False negative and positive results have been found, respectively, in 20–40% and 10% of healthy individuals.^[41]

Similarly, Radfar *et al.* reported in their study^[42] that salivary gland biopsies with 2 to 6 focus score have been found in 15% of healthy individuals, with no clinical signs of xerostomia or keratoconjunctivitis sicca.^[42]

Furthermore, patients affected by some autoimmune disorders not associated with dryness symptoms may also reveal minor salivary gland infiltration.^[43]

Sialography

Sialography is a radiographic study of the salivary glands. Usually, it targets the parotid gland; however, it can also be applicable to the submandibular. It consists of obtaining an X-ray after injecting a contrast medium into the salivary duct [Figure 3a and b]. In SS patients, sialography shows a twisted and dilated duct associated with an uneven distribution of the contrast medium inside the gland [Figure 4 a and b].^[34]

Rubin and Holt^[44] developed a classification for SS diagnosis based on sialography imaging composed of 5 stages [Table 3].

For the RICC, the JEC, as well as the American-European consensus group (AECG), a positive result in the sialography study is included among the SS diagnosis criteria.^[34] However, this technique is less frequently used because it may present false positive and negative results.^[45] Furthermore, it is not indicated when a gland is highly damaged due to the risk of the contrast medium retaining.^[46,47]



Figure 3: (a) Normal sialogram of the parotid gland; (b) Normal sialogram of the submandibular gland.

Despite being considered among the AECG criteria, sialography is not included in the American college of rheumatology (ACR) classification criteria for SS.^[48]

Scintigraphy

Scintigraphy is a noninvasive technique which can be used to assess the function of salivary glands.^[49] Its main advantage compared to other methods is by providing information regarding both salivary gland parenchyma and function.^[50]

Scintigraphy consists on capturing by a detector-type gamma scintillation camera and the emitted radiation of radioisotopes such as Technetium-99m pertechnetate administered intravenously.^[49,50]

Normally, the radioactive tracer is progressively accumulated in the glands (within 10 min of the substance administration), and after 20 to 30 min it is secreted into the mouth.^[49,50] In SS, both the concentration inside the gland and the secretion into the mouth are lower.^[34]

Schall *et al.* proposed a classification for salivary scintigraphy based on the visual evaluation of the uptake

Table 3: Sjögren's syndrome classification based on sialography imaging as developed by Rubin and Holt

Stage	Description
Stage 0	Normal image (without contrast media collection)
Stage 1	Punctuate image (refers to contrast media collection ≤ 1 mm in diameter)
Stage 2	Globular image (contrast media collection between 1 and 2 mm in diameter)
Stage 3	Cavitary image (contrast media collection ≥ 2 mm in diameter)
Stage 4	Destructive image (complete destruction of the gland parenchyma)




Figure 4: Sialogram of Sjögren's syndrome-affected parotid gland (a) and submandibular gland (b) showing a stage 4 according to Rubin and Holt classification

and discharge of the radioactive substance. The glands are consequently graded from 1 (normal) to 4 (severe affection).^[51,52]

Abnormal salivary gland scintigram is included by the AECG among the diagnostic criteria of SS.^[34] However, being rejected by most patients due to its high cost and their fear of a potential subjective risk of radiation damage, this technique is rarely performed. Interestingly, many authors found a correlation between salivary gland scintigraphy, sialography, and positive focus score in a minor salivary gland. The latter being one of the most specific tests in diagnosing SS.^[53-55]

Magnetic resonance and ultrasonography

Magnetic resonance (MR) imaging, MR sialography, and ultrasonography (US) are noninvasive techniques providing precise imaging of salivary glands without the need of contrast media or biopsy procedures.

By allowing multiplanar images with high contrast tissue resolution, MR imaging is widely considered to evaluate the structural alterations of the salivary glands.^[34] In SS, the glandular tissue appears inhomogeneous and speckled with multiple nodules of different sizes.^[56]

In the latter years, MR sialography has widely replaced classical sialography. It has shown highly precise salivary gland assessment, and consequently a reliable SS diagnosis.^[57]

In regards to US, the ability to evaluate all salivary glands at the same time added to the benefit of being cheaper and more available than MR makes it most advantageous. However, due to its delicacy, it should only be performed by proficient and qualified personnel.^[58]

Although these techniques are promising, none of them is considered among the criteria of the AECG.

Raman spectroscopy

Raman spectroscopy (RS) is a spectroscopic technique used to observe the changes of chemical components and the alterations of molecular substructures in the biological tissues, referred to as “molecular fingerprint.”^[59] Xue *et al.* reported that RS can replace the lip biopsy, sometimes invasive, to diagnose pathological minor salivary glands in primary SS.^[60]

According to the authors, lymphocytic infiltration leading to the destruction of the minor salivary glands is

accompanied by a change of the “molecular fingerprint” from the early stages of primary SS.^[60]

Consequently, the content of proteins, nucleic acids, and keratin increases because of inflammatory cells' infiltration and glandular foci formation while the content of lipids decreases as a result of the inflammation and the glandular destruction.^[60]

CONCLUSION

The oral component of SS is characterized by xerostomia resulting from the loss of salivary function due to lymphocytic infiltration of the salivary glands. To evaluate this component, different methods have been used. These methods and their diagnostic value in SS have been reviewed. Assessment of clinical signs and symptoms, salivary flow rate measurement, salivary composition analysis, histopathological and radiologic examinations, and other new advanced techniques are key diagnostic factors to be considered.

Although different conclusions have been presented, every mean should be used for adequately determining the real status of the salivary glands.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Baldini C, Talarico R, Tzioufas AG, Bombardieri S. Classification criteria for Sjögren's syndrome: A critical review. *J Autoimmun* 2012;39:9-14.
2. Jadhav S, Jadhav A, Thopte S, Marathe S, Vhathakar P, Chivte P, *et al.* Sjögren's syndrome: A case study. *J Int Oral Health* 2015;7:72-4.
3. Bowman SJ, Fisher BA. Stratifying primary Sjögren's syndrome: Killers in the balance? *Arthritis Res Ther* 2015;17:351.
4. Valim V, Zandonade E, Pereira AM, de Brito Filho OH, Serrano EV, Musso C, *et al.* Primary Sjögren's syndrome prevalence in a major metropolitan area in Brazil. *Rev Bras Reumatol* 2013;53:24-34.
5. Göransson LG, Haldorsen K, Brun JG, Harboe E, Jonsson MV, Skarstein K, *et al.* The point prevalence of clinically relevant primary Sjögren's syndrome in two Norwegian counties. *Scand J Rheumatol* 2011;40:221-4.
6. Patel R, Shahane A. The epidemiology of Sjögren's syndrome. *Clin Epidemiol* 2014;6:247-55.
7. Giovelli RA, Santos MC, Serrano ÉV, Valim V. Clinical characteristics and biopsy accuracy in suspected cases of Sjögren's syndrome referred to labial salivary gland biopsy. *BMC*

- Musculoskelet Disord 2015;16:30.
8. Payet J, Belkhir R, Gottenberg JE, Bergé E, Desmoulin F, Meyer O, *et al.* ACPA-positive primary Sjögren's syndrome: True primary or rheumatoid arthritis associated Sjögren's syndrome? *RMD Open* 2015;1:e000066.
 9. Neville BW, Damm D, Allen C, Bouquot J. *Oral & maxillofacial pathology*. 2nd Ed. Philadelphia: W.B. Saunders; 2002. p. 398-9.
 10. Hara A, Zero DT. The potential of saliva in protecting against dental erosion. *Monogr Oral Sci* 2014;25:197-205.
 11. Tanida T, Okamoto T, Okamoto A, Wang H, Hamada T, Ueta E, *et al.* Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. *J Oral Pathol Med* 2003;32:586-94.
 12. Coulthard P, Horner K, Sloan P, Theaker E. *Oral and Maxillofacial Surgery, Radiology, Pathology and Oral Medicine*. 2nd ed. Edinburgh: Churchill Livingstone/Elsevier; 2008. p. 210, 212-13.
 13. Cassolato SF, Turnbull RS. Xerostomia: Clinical aspects and treatment. *Gerodontology* 2003;20:64-77.
 14. Ikebe K, Morii K, Kashiwagi J, Nokubi T, Ettinger RL. Impact of dry mouth on oral symptoms and function in removable denture wearers in Japan. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2005;99:704-10.
 15. Scully Crispian. *Oral and maxillofacial medicine: The basis of diagnosis and treatment*. 2nd Ed. Edinburgh: Churchill Livingstone; 2008. p. 17, 31, 41, 79-85.
 16. Veerman EC, van den Keijbus PA, Vissink A, Nieuw Amerongen AV. Human glandular salivas: Their separate collection and analysis. *Eur J Oral Sci* 1996;104:346-52.
 17. Kalk WW, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, Nieuw Amerongen AV. Sialometry and sialochemistry: Diagnostic tools for Sjögren's syndrome. *Ann Rheum Dis* 2001;60:1110-6.
 18. Navazesh M, Kumar SK. Measuring salivary flow: Challenges and opportunities. *J Am Dent Ass* 2008;139:35S-40S.
 19. Manthorpe R, Oxholm P, Prause JU, Schiødt M. The Copenhagen criteria for Sjögren's syndrome. *Scand J Rheumatol* 1986;61(Suppl):19-21.
 20. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, *et al.* Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. *Arthritis Rheum* 1993;36:340-7.
 21. Fox RI, Saito I. Criteria for diagnosis of Sjögren's syndrome. *Rheum Dis Clin North Am* 1994;20:391-407.
 22. Sreebny L, Zhu WX. Sjögren's syndrome: An evaluation of patients who complain of dry mouth and dry eyes. Part 1. Screening tests. *Gerodontology* 1996;13:35-48.
 23. Mandel ID, Baumash H. Sialochemistry in Sjögren's syndrome. *Oral Surg Oral Med Oral Pathol* 1976;41:182-7.
 24. Atkinson JC. The role of salivary measurements in the diagnosis of salivary autoimmune diseases. *Ann N Y Acad Sci* 1993;694:238-51.
 25. Vissink A, Panders AK, Nauta JM, Ligeon EE, Nikkels PGJ, Kallenberg CG. Applicability of saliva as a diagnostic fluid in Sjögren's syndrome. *Ann N Y Acad Sci* 1993;694:325-9.
 26. Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. *Ann Rheum Dis* 2007;66:107-12.
 27. Vissink A, Spijkervet FK, Van Nieuw AA. Aging and saliva: A review of the literature. *Spec Care Dentist* 1996;16:95-103.
 28. Davies AN, Shorthose K. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. *Cochrane Database Syst Rev* 2007:CD003782.
 29. van der Reijden WA, van der Kwaak JS, Veerman EC, Nieuw Amerongen AV. Analysis of the concentration and output of whole salivary constituents in patients with Sjögren's syndrome. *Eur J Oral Sci* 1996;104(Pt 1):335-40.
 30. Baldini C, Giusti L, Ciregia F, Da Valle Y, Giacomelli C, Donadio E, *et al.* Proteomic analysis of saliva: A unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. *Arthritis Res Ther* 2011;13:R194.
 31. dos Anjos Corvo MA, Eckley CA, Liquidato BM, Castilho GL, de Arruda CN. pH salivary analysis of subjects suffering from Sjögren's Syndrome and laryngopharyngeal reflux. *Braz J Otorhinolaryngol* 2012;78:81-6.
 32. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. *J Autoimmun* 2010;34:400-7.
 33. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. *Oral Surg Oral Med Oral Pathol* 1974;37:217-29.
 34. Gomes P de S, Juodzbaly G, Fernandes MH, Guobis Z. Diagnostic approaches to Sjögren's syndrome: A literature review and own clinical experience. *J Oral Maxillofac Res* 2012;3:e3.
 35. Voulgarelis M, Moutsopoulos HM. Mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: Risks, management, and prognosis. *Rheum Dis Clin North Am* 2008;34:921-33.
 36. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjögren's disease. *J Clin Pathol* 1968;21:656-60.
 37. Barone F, Campos J, Bowman S, Fisher BA. The value of histopathological examination of salivary glands biopsies in diagnosis, prognosis and treatment of Sjögren's syndrome. *Swiss Med Wkly* 2015;145:ww14168.
 38. Daniels TE, Cox D, Shiboski CH, Schiødt M, Wu A, Lanfranchi H, *et al.* Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. *Arthritis Rheum* 2011;63:2021-30.
 39. Haldorsen K, Moen K, Jacobsen H, Jonsson R, Brun JG. Exocrine function in primary Sjögren syndrome: Natural course and prognostic factors. *Ann Rheum Dis* 2008;67:949-54.
 40. Tarpley TM, Anderson L, White CL. Minor salivary gland involvement in Sjögren's syndrome. *Oral Surg Oral Med Oral Pathol* 1974;37:64-74.
 41. Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. *Arch Med Res* 2002;33:95-106.
 42. Radfar L, Kleiner DE, Fox PC, Pillemer SR. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. *Arthritis Rheum* 2002;47:520-4.
 43. Vitali C, Tavoni A, Simi U, Marchetti G, Vigorito P, d'Ascanio A, *et al.* Parotid sialography and minor salivary gland biopsy in the diagnosis of Sjögren's syndrome. A comparative study of 84 patients. *J Rheumatol* 1988;15:262-7.
 44. Rubin P, Holt J. Secretory sialography in diseases of the major salivary glands. *Am J Roentgenol Radium Ther Nucl Med* 1957;77:575-98.
 45. Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. *Arch Med Res* 2002;33:95-106.
 46. Valdez IH, Fox PC. Diagnosis and management of salivary

- dysfunction. *Crit Rev Oral Biol Med* 1993;4:271-7.
47. Schortinghuis J, Pijpe J, Spijkervet FK, Vissink A. Retention of lipiodol after parotid gland sialography. *Int J Oral Maxillofac Surg* 2009;38:346-9.
 48. Shiboski S, Shiboski C, Criswell L, Baer A, Challacombe S, Lanfranchi H, *et al.* American College of Rheumatology classification criteria for Sjögren's syndrome: A data-driven, expert consensus approach in the SICCA cohort. *Arthritis Care Res* 2012;64:475-487.
 49. Cohen-Brown G, Ship JA. Diagnosis and treatment of salivary gland disorders. *Quintessence Int* 2004;35:108-23.
 50. Vinagre F, Santos MJ, Prata A, da Silva Canas J, Santos AI. Assessment of salivary gland function in Sjögren's syndrome: The role of salivary gland scintigraphy. *Autoimmun Rev* 2009;8:672-6.
 51. Schall GL, Larson SM, Anderson LG, Griffith JM. Quantification of parotid gland uptake of pertechnetate using a gamma scintillation camera and a "region-of-interest" system. *Am J Roentgenol Radium Ther Nucl Med* 1972;115:689-97.
 52. Schall GL, Anderson LG, Wolf RO, Herdt JR, Tarpley TM Jr, Cummings NA, *et al.* Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy. *JAMA* 1971;216:2109-16.
 53. Aung W, Yamada I, Umehara I, Ohbayashi N, Yoshino N, Shibuya H, *et al.* Sjögren's syndrome: Comparison of assessment with quantitative salivary gland scintigraphy and contrast sialography. *J Nucl Med* 2000;41:257-62.
 54. Aung W, Murata Y, Ishida R, Takahashi Y, Okada N, Shibuya H. Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren's syndrome. *J Nucl Med* 2001;42:38-43.
 55. Shizukuishi K, Nagaoka S, Kinno Y, Saito M, Takahashi N, Kawamoto M, *et al.* Scoring analysis of salivary gland scintigraphy in patients with Sjögren's syndrome. *Ann Nucl Med* 2003;17:627-31.
 56. Niemelä RK, Takalo R, Pääkkö E, Suramo I, Päivänsalo M, Salo T, *et al.* Ultrasonography of salivary glands in primary Sjögren's syndrome. A comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glands. *Rheumatology* 2004;43:875-9.
 57. Ohbayashi N, Yamada I, Yoshino N, Sasaki T. Sjögren syndrome: Comparison of assessments with MR sialography and conventional sialography. *Radiology* 1998;209:683-8.
 58. Bialek EJ, Jakubowski W, Zajkowski P, Szopinski KT, Osmolski A. US of the major salivary glands: Anatomy and spatial relationships, pathologic conditions, and pitfalls. *Radiographics* 2006;26:745-63.
 59. Yan B, Li Y, Yang G, Wen ZN, Li ML, Li LJ. Discrimination of parotid neoplasms from the normal parotid gland by use of Raman spectroscopy and support vector machine. *Oral Oncol* 2011;47:430-5.
 60. Xue L, Sun P, Ou D, Chen P, Chen M, Yan B. Diagnosis of pathological minor salivary glands in primary Sjögren's syndrome by using Raman spectroscopy. *Lasers Med Sci* 2014;29:723-8.